Phase 1

HER2 TKI, Zongertinib

This compound is under investigation, further information will be available soon.

HER2 is a member of the ErbB family of receptor tyrosine kinases. Mutations in HER2 can lead to overexpression and overactivation, which can in turn result in uncontrolled cell production, inhibition of cell death, and promotion of tumor growth and spread. HER2 gene alterations are seen across a number of different cancer types.  

BI 1810631 is an irreversible HER2-selective tyrosine kinase inhibitor (TKI) currently being investigated in a phase I clinical trial (clinicaltrials.gov identifier: NCT04886804).